Therefore, the possibility of having microglia (using minocycline) and mastocytes activation (with GRH-R antagonists) as therapeutic targets opens the possibility of their modulation as treatment for various neuropsychiatric disorders, viral infections, and other neuroinflammatory pathologies of the CNS. Here, GNRHR is linked to viral infectious disease.